QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nutriband-discloses-84m-private-placement-representing-210m-shares-of-common-stock-at-4-per-share-company-targets-505b2-nda-to-fda-for-marketing-approval-of-aversa-fentanyl-in-q1-2025

Company says that for each Share of common stock purchased the investor receives a five-year warrant to purchase two shares of ...

 why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

 why-luxurban-hotels-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fo...

 nutriband-provided-an-overview-of-the-clinical-development-and-regulatory-pathway-for-its-lead-product-aversa-fentanyl-an-abuse-deterrent-fentanyl-transdermal-patch

NDA will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials neede...

Core News & Articles

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today ...

 nutriband-q2-eps-011-up-from-012-yoy-sales-65593k-up-from-45615k-yoy

Nutriband (NASDAQ:NTRB) reported quarterly losses of $(0.11) per share. This is a 8.33 percent increase over losses of $(0.12) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION